The startup develops proprietary lipid nanoparticles (LNPs) for targeted drug delivery in hard-to-treat cancers, metabolic diseases, and fibrosis. By integrating nanotechnology with AI and bioinformatics, the company enables real-time tracking of drug efficacy across various cell types, significantly accelerating drug discovery timelines.
Funding
$3.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
A significant challenge in RNA therapeutics is delivering RNA-based drugs to specific target cells and tissues while protecting them from degradation. Current delivery methods often lack the precision needed for effective treatment of diseases beyond the liver.
Solution
Barcode Nanotech develops lipid nanoparticle (LNP)-based delivery vehicles for RNA and DNA therapeutics, enabling targeted delivery to specific cells and tissues. The company's platform utilizes a proprietary library of novel lipids and an in vivo screening process coupled with AI analysis to identify optimal delivery vehicles for various targets. This approach allows for the development of RNA therapeutics and vaccines with enhanced selectivity and activity in designated cells and tissues, addressing the challenge of delivering RNA-based drugs beyond the liver. The platform facilitates the simultaneous screening of hundreds of different nanoparticle formulations in vivo, improving the efficiency of identifying selective delivery options.
Target Audience
The primary target audience includes pharmaceutical companies and researchers developing RNA therapeutics and vaccines, seeking advanced delivery solutions for targeted drug delivery.
Features
- Proprietary library of novel lipids for RNA and DNA encapsulation and delivery
- LNP-based delivery system optimized for selective and efficient targeting
- In vivo mass screening platform for simultaneous evaluation of hundreds of nanoparticle formulations
- AI-powered analysis tools for identifying optimal delivery vehicles
- Ability to target a range of tissues and organs, including the liver, lung, kidney, spleen, and brain
- Molecular barcoding technology for quantifying nanoparticle biodistribution at single-cell resolution